Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. (Afatinib post IO)

First published 18/08/2020

Last updated 16/10/2026

EU PAS number:

EUPAS36813

Study

Finalised

Download as PDF

Documents

Study protocol

Updated protocol

1200-0335_CTP_final-rule_Redacted.pdf

First published: 21/09/2026

English (1.35 MB - PDF) View document

Study results

1200-0335_Synopsis.pdf

English (438.59 KB - PDF) View document

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. (Afatinib post IO)

Secondary tabs

Share this page